GBT new logo.png
GBT Appoints Industry Leader David L. Johnson as Chief Commercial Officer
March 06, 2018 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the “Company”) (Nasdaq:GBT) today announced the appointment of David L. Johnson as chief...
GBT new logo.png
GBT Announces New Employment Inducement Grants
March 05, 2018 16:05 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ:GBT) today announced that on March 1, 2018, the compensation committee of...
GBT new logo.png
GBT Announces Participation at Upcoming Investor Conferences in March
March 05, 2018 16:05 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in March...
GBT new logo.png
GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial Results
February 27, 2018 16:07 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported recent business progress and financial results for the fourth quarter...
GBT new logo.png
GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference
February 07, 2018 16:05 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the Leerink Partners 7th Annual Global...
GBT new logo.png
GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)
January 09, 2018 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted...
GBT new logo.png
GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 03, 2018 16:05 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare...
GBT new logo.png
GBT Appoints Wendy L. Yarno to Board of Directors
December 22, 2017 09:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the appointment of Wendy L. Yarno to the company’s board of...
GBT new logo.png
Global Blood Therapeutics Prices a $100.0 Million Common Stock Public Offering
December 15, 2017 09:03 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and...
GBT new logo.png
Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
December 14, 2017 16:01 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and...